40 million euro for cancer treatment researchJuly 27, 2018
Hat: 40 million euro for cancer treatment research
Funding Scheme: 2018-07-27
Pgm2014 2020: Yes
With the support of the Juncker Plan, the EIB has granted a loan to the biotechnology company Nanobiotix.
The loan will help finance research and development by Nanobiotix of innovative cancer treatments.
The RDI expenditure programme will include the development of Nanobiotix’s novel nanoparticle radio-enhancer product called NBTXR3. The activities under the programme will include the design, as well as the conduct, of clinical trials and any tasks to bring NBTXR3 to the market. The development programme primarily targets indications in Soft Tissue Sarcomas, Head and Neck cancers and other solid tumours.
Since its launch three years ago, the Juncker Plan has been highly successful in Europe, surpassing its initial objectives by mobilising EUR 335 billion, EUR 20 billion above the originally forecasted target of EUR 315 billion. France is the largest beneficiary of the Juncker Plan with more than EUR 50 billion worth of additional investments mobilised since mid-2015 under the plan.
Url description: Press room - European Commission